End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age

X. Castellsagué, N. Mũoz, P. Pitisuttithum, D. Ferris, J. Monsonego, K. Ault, J. Luna, E. Myers, S. Mallary, O. M. Bautista, J. Bryan, S. Vuocolo, R. M. Haupt, A. Saah

Research output: Contribution to journalArticlepeer-review

207 Scopus citations

Fingerprint Dive into the research topics of 'End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age'. Together they form a unique fingerprint.

Medicine & Life Sciences